MX2021004273A - Proteinas de citomegalovirus modificadas y complejos estabilizados. - Google Patents

Proteinas de citomegalovirus modificadas y complejos estabilizados.

Info

Publication number
MX2021004273A
MX2021004273A MX2021004273A MX2021004273A MX2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A
Authority
MX
Mexico
Prior art keywords
hcmv
complexes
modified
stabilized complexes
modified cytomegalovirus
Prior art date
Application number
MX2021004273A
Other languages
English (en)
Spanish (es)
Inventor
Enrico Malito
Sumana Chandramouli
Andrea Carfi
Matthew James Bottomley
Kate Luisi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2021004273A publication Critical patent/MX2021004273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021004273A 2018-10-17 2019-10-15 Proteinas de citomegalovirus modificadas y complejos estabilizados. MX2021004273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746804P 2018-10-17 2018-10-17
PCT/IB2019/058777 WO2020079586A1 (en) 2018-10-17 2019-10-15 Modified cytomegalovirus proteins and stabilized complexes

Publications (1)

Publication Number Publication Date
MX2021004273A true MX2021004273A (es) 2021-12-10

Family

ID=68296588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004273A MX2021004273A (es) 2018-10-17 2019-10-15 Proteinas de citomegalovirus modificadas y complejos estabilizados.

Country Status (8)

Country Link
US (2) US11932669B2 (cg-RX-API-DMAC7.html)
EP (1) EP3866845A1 (cg-RX-API-DMAC7.html)
JP (1) JP7584405B2 (cg-RX-API-DMAC7.html)
CN (1) CN113271968B (cg-RX-API-DMAC7.html)
BR (1) BR112021006812A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004273A (cg-RX-API-DMAC7.html)
WO (1) WO2020079586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性fimh
US20250325656A1 (en) * 2022-05-20 2025-10-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
WO2001000648A1 (en) 1999-06-25 2001-01-04 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
US8778359B2 (en) 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
RS61993B1 (sr) * 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
MX2016014660A (es) 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
BE1023213B1 (fr) 2014-05-27 2016-12-21 Glaxosmithkline Biologicals Sa Complexes issus du cytomegalovirus et leurs utilisations
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same

Also Published As

Publication number Publication date
WO2020079586A9 (en) 2021-05-06
CA3116175A1 (en) 2020-04-23
US12384819B2 (en) 2025-08-12
US20240383949A1 (en) 2024-11-21
BR112021006812A2 (pt) 2021-07-20
JP2022505094A (ja) 2022-01-14
US11932669B2 (en) 2024-03-19
US20210277067A1 (en) 2021-09-09
JP7584405B2 (ja) 2024-11-15
EP3866845A1 (en) 2021-08-25
WO2020079586A1 (en) 2020-04-23
CN113271968B (zh) 2024-06-14
CN113271968A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
MX2022006759A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
PH12018501882A1 (en) Binding proteins and methods of use thereof
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
MX382518B (es) Antigenos de citomegalovirus y su uso.
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
MX2018000621A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
AR122196A2 (es) Proteína de unión a ilt7, célula huésped, polinucleótido, vector, y métodos relacionados
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
WO2015132675A3 (en) Methods and compositions for modifying the immune response
CY1124911T1 (el) Συνθεσεις πεπτιδιων και μεθοδοι χρησης
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112017005660A2 (pt) novos ativadores de guanilato ciclase solúvel e sua utilização
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
EA201990822A1 (ru) Иммуномодулирующие слитые белки
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas
BR112021013206A2 (pt) Bibliotecas de peptídeos e respectivos métodos de uso
EA202090838A1 (ru) Иммуномодулирующие слитые белки